Innate Pharma (IPHA)

Innate Pharma (IPHA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $160M; returns 1 day +0.0%, 1 week +4.9%, 1 year -31.5%.

Innate Pharma SA is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company's approach centers around harnessing the innate immune system through therapeutic antibodies, including multi-specific NK cell engagers (via its ANKET® platform) and antibody-drug conjugates (ADCs).

Groups IPHA belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Cancer Therapeutics
• Immunotherapy
• Healthcare
• Biopharmaceutical
• Antibody Therapeutics
• Antibody-Drug Conjugates
• Clinical Stage
• Monoclonal Antibodies
• Life Sciences

IPHA financial model: income statement, cash flow and balance sheet